Latest 10-K annual reports

EMCOR Group, Inc. reported record revenues of $16.99 billion and net income of $1.27 billion for 2025, driven by strong U.S. construction demand and strategic acquisitions, alongside a significant dividend increase.

Novavax reported a significant financial turnaround in 2025, achieving net income of $440.3 million, driven by strategic partnership milestones and cost reductions, while securing new collaborations for its Matrix-M adjuvant.

NCR Voyix Corporation reported a 5% decrease in total revenue to $2.687 billion for 2025, while Adjusted EBITDA increased by 22% to $425 million, driven by cost reduction initiatives and a shift to recurring revenue.

Thryv Holdings, Inc. reported a net income of $0.3 million for fiscal year 2025, driven by significant SaaS revenue growth and a strategic exit from its legacy Marketing Services segment by 2028.

Vital Farms reported a 25% increase in net revenue to $759.4 million for fiscal year 2025, alongside significant investments in infrastructure and a new stock repurchase program.

Viridian Therapeutics, Inc. announced a significant revenue participation right sale of up to $300 million and provided updates on its advanced Thyroid Eye Disease (TED) programs, veligrotug and elegrobart, alongside its FcRn and TSHR inhibitor portfolios.

FTI Consulting's 2025 annual report reveals revenue and Adjusted EBITDA growth, but a decline in net income and operating cash flow, alongside significant share repurchases.

Crescent Biopharma details its oncology pipeline, strategic partnerships, and financial position in its 2025 annual report, highlighting significant capital raises and ongoing clinical development.

Helix Energy Solutions Group, Inc. reported a 5% decrease in consolidated net revenues for 2025, driven by lower Well Intervention and Production Facilities revenues, partially offset by growth in Robotics and Shallow Water Abandonment segments.

Immunic, Inc. announced a significant private placement raising $187 million, extending its operational runway while progressing its lead multiple sclerosis and celiac disease drug candidates through clinical trials and securing key intellectual property.

Kymera Therapeutics reports significant progress in its clinical pipeline, including positive Phase 1b results for KT-621 in Atopic Dermatitis, new collaborations, and substantial capital raises, despite continued operating losses.

Shentel reports increased revenue driven by fiber expansion but faces higher losses from continuing operations, significant debt, and announces a 10% workforce reduction.

Entrada Therapeutics reports a significant net loss for 2025 despite advancing multiple clinical programs for Duchenne muscular dystrophy and inherited retinal diseases, with cash runway into Q3 2027.

West Bancorporation, Inc. announced a significant increase in net income and earnings per share for 2025, driven by improved net interest income and efficiency.

Zai Lab Limited reported a 15% increase in total revenue to $460.2 million and a 32% decrease in net loss to $175.5 million for 2025, driven by commercial product performance and pipeline advancements.

Bridgewater Bancshares, Inc. announced robust financial results for the fiscal year ended December 31, 2025, driven by significant loan and deposit growth and improved net interest income.

Phathom Pharmaceuticals reported significant revenue growth in 2025 driven by VOQUEZNA sales, while narrowing net losses and securing new financing to support its path to operating profitability by Q3 2026.

GigaCloud Technology Inc. announced robust financial results for the fiscal year ended December 31, 2025, driven by significant growth in its B2B ecommerce marketplace and strategic acquisitions.

Papa Johns International reports a significant drop in 2025 net income and EPS, driven by transformation costs and North America sales declines, despite international growth.

NovoCure Limited reports 8% revenue growth to $655.4 million in 2025, driven by Optune Gio adoption and new product launches, despite continued operating losses and increased R&D spending.

Palmer Square Capital BDC Inc. reports a net decrease in net assets from operations for the fiscal year ended December 31, 2025, driven by significant unrealized losses on investments.

LeMaitre Vascular, Inc. announced robust financial results for 2025, driven by increased sales, improved margins, and strategic expansions, alongside an increased quarterly dividend.

Matador Resources Company achieved record oil and natural gas production in 2025, alongside strategic midstream expansions and capital returns, despite lower commodity prices impacting net income and reserve valuations.

Certara, Inc. announced a 9% increase in total revenues to $418.8 million and significantly reduced its net loss to $1.6 million for the fiscal year ended December 31, 2025, driven by strong demand and strategic acquisitions.

Nuvalent, Inc. reports significant progress in its targeted oncology pipeline, including an FDA NDA acceptance for zidesamtinib and positive topline data for neladalkib, while continuing to incur substantial net losses.

Eos Energy Enterprises, Inc. announced a 632% revenue increase in 2025, driven by strategic capital raises and operational milestones, despite continued net losses as it scales its zinc-based battery technology.

Trulieve Cannabis Corp. reports a slight revenue dip but improved net loss and increased Adjusted EBITDA for 2025, while actively managing debt and anticipating federal cannabis reclassification.

Ducommun Incorporated reported a net loss of $33.9 million for 2025, primarily driven by a significant $150.0 million Guaymas fire litigation settlement, despite a 4.9% increase in net revenues to $824.7 million.

Claritev Corporation reported a 3.7% increase in total revenue for 2025, reaching $965.4 million, alongside a significant reduction in net loss to $284.3 million, while addressing substantial indebtedness and internal control weaknesses.

Arhaus, Inc. reported an 8.5% increase in net revenue to $1.38 billion for fiscal year 2025, alongside a slight decrease in net income and ongoing efforts to remediate material weaknesses in internal control over financial reporting.